Skip to main
VNRX
VNRX logo

Volitionrx Limited (VNRX) Stock Forecast & Price Target

Volitionrx Limited (VNRX) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

VolitionRX Ltd is poised for topline growth driven by potential upfront and milestone payments, along with future recurring royalties. The company is expanding its customer base for the Nu.Q Discover services through a strategic co-marketing agreement, enhancing its market reach. Additionally, the recent research license and exclusive commercial option rights agreement with the Immunoassay Technology Center of Werfen indicates a strong partnership that could further bolster Volition’s position in the diagnostics market.

Bears say

VolitionRX Ltd faces significant risks that may negatively impact its financial stability and future performance, including the potential for failures in the clinical development of its diagnostic products. Additionally, the company could struggle to secure necessary license agreements and may fail to gain market traction, which would further hinder revenue growth. Furthermore, concerns regarding dilution and going concern issues, including the risk of delisting, create added uncertainties surrounding the company's financial outlook.

Volitionrx Limited (VNRX) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Volitionrx Limited (VNRX) Forecast

Analysts have given Volitionrx Limited (VNRX) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Volitionrx Limited (VNRX) has a Strong Buy consensus rating as of Oct 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Volitionrx Limited (VNRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.